Kaposi Sarcoma – Pipeline Review, 2024

The most common type of Kaposi sarcoma, which is a rare cancer, is associated with advanced HIV. All forms of Kaposi sarcoma are caused by Kaposi sarcoma herpesvirus (KSHV). The disease causes patches of abnormal tissue to grow in the lining of the mouth, under the skin, nose, throat, in lymph nodes, or in other organs and is usually found in people with weak immune systems, due to HIV/AIDS. Kaposi Sarcoma is the most common cancer in the population suffering from HIV in Africa. In the U.S., the disease is relatively uncommon with only 6 cases per million people every year.

The current treatment of Kaposi sarcoma in patients with HIV is antiretroviral therapy. Surgery, photodynamic therapy, radiation therapy, and medication including chemotherapy, targeted therapy, immunotherapy, etc. are the other treatment options for Kaposi sarcoma.

To know how our report can help streamline your business, Speak to Analyst

At present, majority of clinical trials are being performed by universities, with only a few in the late stage. For example, a clinical trial for Pomalidomide, which is being conducted by National Cancer Institute (NCI) for the treatment of Kaposi sarcoma, is in Phase 3.

To know how our report can help streamline your business, Speak to Analyst

Currently, more than 50% of the pipeline candidates for Kaposi Sarcoma are in phase-2 and around 75% of the studies are active. Majority of the studies have been sponsored by universities. 

Report Description 

The report on ‘Kaposi Sarcoma – Pipeline Review, 2024’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Kaposi sarcoma. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Kaposi Sarcoma.

The report on ‘Kaposi Sarcoma – Pipeline Review, 2024’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players. 

Report Scope 

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases and relevant conferences 

Report Methodology 

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases 

Reasons to Buy this Report 

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for Kaposi Sarcoma
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Kaposi sarcoma
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business